With Biosimilars On The Horizon, Some Brands Are At Risk
Executive Summary
With the establishment of a regulatory framework for biosimilars in the U.S., the threat of low-cost competition to the branded biologic drug industry is closer to becoming a reality in the world's largest drug market
You may also be interested in...
Teva, Eyeing Follow-Ons For Most Biologics, Starts With Amgen's Neupogen
Teva is looking into developing follow-on products for most of the biologics currently available on the U.S. market, William S. Marth, president and CEO of Teva North America, said in an interview
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials